Feb 20, 2012

Dako Enters into an Additional Collaboration with Amgen on Developing a Companion Diagnostic Test (pharmDx™) for an Investigational Cancer Therapy in Clinical Development

Dako, a world leading independent cancer diagnostic supplier with 45 years of experience in pathology, announced today that it has entered into a new collaboration agreement with Amgen Inc. (Nasdaq: AMGN) on the development of a diagnostic test for an Amgen cancer drug candidate in clinical development.

“It is Dako’s mission to fight cancer. Hence, we are pleased to be chosen as Amgen’s partner once again for the development of companion diagnostics linked to Amgen’s investigational targeted therapies,” says Lars Holmkvist, Dako’s chief executive officer.

In January 2012, Dako announced a collaboration agreement with Amgen Inc. introducing a new business model which supports the concurrent development of drug and diagnostics for a rare but deadly cancer – something that up to this point has been difficult to achieve in the industry.

“This new collaboration with Amgen underlines Dako’s commitment to advance personalized medicine in cancer treatment as the selection of patients most likely to benefit from a specific treatment will increase the probability of therapeutic success for cancer patients suffering," Lars Holmkvist adds.

Today’s news comes on the heels of several pharmDx™ collaborative agreements recently announced by Dako.

The demand for personalized medicine is increasing with the recognition that it may provide a way to improve patient care and manage healthcare costs by targeting treatments to individuals more likely to benefit from specific therapies.

Media contact
Maia Fredtoft Søchting
Corporate Communications
Dako Denmark A/S
Tel. +45 25 46 10 83

About Dako
Dako, based in Denmark, is a global leader in tissue-based cancer diagnostics. Hospital and research laboratories worldwide use Dako’s know-how, reagents, instruments and software to make accurate diagnoses and determine the most effective treatment for patients suffering from cancer. Employing more than 1,000 people and being present in more than 80 countries, Dako covers essentially all of the anatomic pathology markets globally. Dako is owned by private equity fund EQT V. www.dako.com

Country selection

Your Dako Account indicates that you are based in , you will be transfered to the web site for

Basket emptied

Your basket was emptied because of the country change.

Country selection

United States of America appears to be your location. To view country specific information on the Dako web site, please accept or change country below.


Dako Cookie Policy
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. Privacy Statement



Get in Touch with Dako in Denmark

  • Pathology Products and Specific Proteins
    Dako Denmark A/S

    info.dk@dako.com
    +45 44 85 97 56
    +45 44 85 84 29

    Produktionsvej 42
    DK-2600 Glostrup

  • Flow Cytometry Products and Specific Proteins
    Electra-Box Diagnostica ApS

    ordre.danmark@electrabox.com
    +45 44 53 62 11
    +45 44 53 62 12

    Hvidsværmervej 147
    DK-2610 Rødovre

Detailed contact information

Submit an Inquiry

How would you like us to follow up?


Your session expired

You have been logged out. Log in again to retrieve your Cart.